We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.59 | 2.17% | 27.77 | 27.94 | 27.12 | 27.21 | 70,056,383 | 00:01:31 |
From May 2021 to May 2024
By Matt Grossman
Pfizer Inc. and BioNTech SE's Covid-19 vaccine showed strong safety and efficacy in children aged 12 to 15 in a Phase 3 trial of its use among that cohort, the companies said Monday.
Data from the trial showed that the vaccine was 100% effective against Covid-19 from seven days after the second dose through more than four months after the second dose, the companies said. There were no serious safety concerns observed in people over six months of safety follow-up, Pfizer and BioNTech said.
The data will be the basis for a regulatory submission seeking full approval for the vaccine in people aged 12 to 15. The vaccine is now available to people that age in the U.S. via an emergency-use authorization from the Food and Drug Administration.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
November 22, 2021 07:14 ET (12:14 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
